Tradestie Institutional Equity Comparison Engine

NBIX vs TAK โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

NBIX Overall Edge

NBIX Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Neurocrine Biosciences Inc (NBIX) driven by superior Valuation, Growth & Margin, Options & Structure while TAK counters with relative strength in Momentum & Technical. Fundamentally, NBIX trades at 13.6x Forward P/E with 26.6% operating margin (+41.2% YoY revenue) versus TAK at 12.7x Forward P/E and 16.6% operating margin (+6.7% YoY). In options structure, NBIX sits in CONSOLIDATION (22nd %ile IV; Dealer Gamma Walls on Pro) against TAK sits in UNCLASSIFIED (5th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner NBIX
NBIX 13.6x vs TAK 12.7x Fwd P/E
Growth & Margin Winner NBIX
Op Margin 26.6% vs 16.6% ยท YoY +41.2% vs +6.7%
Momentum & Technical Winner TAK
1Y +14.7% vs +51.8% ยท 52W Pos 68% vs 97%
Options & Structure Winner NBIX
CONSOLIDATION (22nd %ile IV) vs UNCLASSIFIED (5th %ile IV)
NBIX NASDAQ
Neurocrine Biosciences Inc
Biological Products, (No Disgnostic Substances)
$165.34
-1.23% 1D
Market Cap $17.1B
1M Return +21.84%
1Y Return +14.69%
Forward P/E 13.6x
Unified AI Score
30.3 / 100 SELL
Tech 50.0 Fund 36.0 Flow 68.0 Mom 50.0
TAK NYSE
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
1M Return +9.89%
1Y Return +51.79%
Forward P/E 12.7x
Unified AI Score
48.0 / 100 HOLD
Tech 43.0 Fund 44.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NBIX +14.69% TAK +51.79% Spread: +37.1 pp (TAK Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
NBIX TTM Op. Margin: 26.6% TAK TTM Op. Margin: 16.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NBIX vs TAK. Trailing 12-month operating profitability (NBIX 26.6% vs TAK 16.6%) and valuation multiples (NBIX 13.6x vs TAK 12.7x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NBIX (5) vs TAK (5)
Institutional Metric NBIX TAK Criterion Row Winner
Market Capitalization Scale $17.1B $67.5B Larger Scale TAK
Trailing P/E Ratio Valuation 25.1x N/M Lower Multiple NBIX
Forward P/E Ratio Valuation 13.6x 12.7x Lower Multiple TAK
Revenue Growth (YoY) Growth +41.2% +6.7% Higher Growth NBIX
Operating Margin (TTM) Profitability 26.6% 16.6% Higher Margin NBIX
Net Profit Margin Profitability 19.0% 0.9% Higher Margin NBIX
Return on Equity (ROE) Capital Efficiency 20.4% 0.6% Higher ROE NBIX
52-Week Range Position Momentum 68% ($122โ€“$186) 97% ($14โ€“$22) Stronger Trend TAK
Beta / 30D Volatility Risk Regime 0.60ฮฒ ยท 54% Vol -0.02ฮฒ ยท 22% Vol Lower Realized Risk TAK
Unified Institutional Score Composite Signal 30.3 / 100 (SELL) 48.0 / 100 (HOLD) Higher Composite TAK

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NBIX vs TAK Buy Guide
NBIX CONSOLIDATION
91d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 22nd %ile
IV Regime Compressed (<25th %ile)
Live NBIX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
TAK UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live TAK Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NBIX nor TAK registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.